Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grass pollen allergy vaccine - Circassia

Drug Profile

Grass pollen allergy vaccine - Circassia

Alternative Names: Grass-SPIRE; Grass-Synthetic Peptide Immuno-Regulatory Epitope; ToleroMune Grass

Latest Information Update: 08 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Circassia
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptide vaccines; Peptides; Plant allergy immunotherapies
  • Mechanism of Action Immunosuppressants; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 21 Jun 2016 Circassia terminates a phase II/III trial in Seasonal allergic rhinitis (In adolescents, In adults) in USA due to the availability of results from another study (NCT02795273)
  • 24 Jun 2015 Phase-II development is ongoing in Canada
  • 31 Dec 2014 Circassia initiates TG002 and TG004 phase II trials for Seasonal allergic rhinitis in Canada prior to December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top